Xia

Hong Kong Heritage Discovery Centre holds "Light of Jinsha - The Ancient Shu Civilisation" exhibition

Retrieved on: 
Friday, December 30, 2022

HONG KONG, Dec 30, 2022 - (ACN Newswire) - An exhibition entitled "Light of Jinsha - The Ancient Shu Civilisation" is now open at the Hong Kong Heritage Discover Centre.

Key Points: 
  • HONG KONG, Dec 30, 2022 - (ACN Newswire) - An exhibition entitled "Light of Jinsha - The Ancient Shu Civilisation" is now open at the Hong Kong Heritage Discover Centre.
  • The "Light of Jinsha - The Ancient Shu Civilisation" exhibition opens from December 30 to March 29, 2023 at the Hong Kong Heritage Discovery Centre.
  • The Jinsha site, a major archaeological discovery in 2001, is another political, economic and cultural centre established by the ancient Shu people in Chengdu Plain after the Sanxingdui civilisation.
  • The exhibition is held at the Hong Kong Heritage Discovery Centre, Kowloon Park, Haiphong Road, Tsim Sha Tsui until March 29, 2023.

Bayer Initiates Phase III Study Program for Investigational Oral FXIa Inhibitor Asundexian

Retrieved on: 
Sunday, August 28, 2022

The underlying science of FXIa and Phase II PACIFIC data provide a foundation on which to advance asundexian forward into the OCEANIC Phase III program, one of the largest Phase III endeavors Bayer has undertaken.1-2

Key Points: 
  • The underlying science of FXIa and Phase II PACIFIC data provide a foundation on which to advance asundexian forward into the OCEANIC Phase III program, one of the largest Phase III endeavors Bayer has undertaken.1-2
    The PACIFIC clinical trials form part of the broadest Phase IIb FXIa program in the world, involving more than 4,000 patients to date.3-5 The program is part of Bayers commitment to address unmet needs in a growing range of underserved cardiovascular patient communities.
  • Asundexian is a once-daily, oral investigational agent and has not been approved by any health authority for use in any country, for any indication.
  • Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack (PACIFIC-AMI).
  • Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.

Guardant Health and Adicon announce strategic partnership to offer comprehensive genomic profiling tests to accelerate development of new cancer therapies in China

Retrieved on: 
Wednesday, July 6, 2022

SINGAPORE, July 6, 2022 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Adicon Holdings Limited, a leading independent clinical laboratory company based in China, today announced a strategic partnership to offer Guardant Health's comprehensive genomic profiling (CGP) tests to biopharmaceutical companies conducting clinical trials in China.

Key Points: 
  • "Our partnership with Adicon marks another important milestone for Guardant Health, and we are excited to bring our comprehensive genomic profiling tests and services to researchers in China," said Helmy Eltoukhy, Guardant Health co-CEO.
  • [1], [2]
    "We are very excited to be partnering with Guardant Health, a global leader in CGP testing, to bring a world-class testing platform to China.
  • "With our CAP accredited laboratory in Shanghai, we are delighted to partner with Guardant Health to make its cancer tests available for biopharmaceutical partners in China."
  • Guardant Health has commercially launched Guardant360, Guardant360 CDx, Guardant360 TissueNext, Guardant360 Response, and GuardantOMNI tests for advanced stage cancer patients, and Guardant Reveal for early-stage cancer patients.

Guardant Health and Adicon announce strategic partnership to offer comprehensive genomic profiling tests to accelerate development of new cancer therapies in China

Retrieved on: 
Wednesday, July 6, 2022

SINGAPORE, July 6, 2022 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Adicon Holdings Limited, a leading independent clinical laboratory company based in China, today announced a strategic partnership to offer Guardant Health's comprehensive genomic profiling (CGP) tests to biopharmaceutical companies conducting clinical trials in China.

Key Points: 
  • "Our partnership with Adicon marks another important milestone for Guardant Health, and we are excited to bring our comprehensive genomic profiling tests and services to researchers in China," said Helmy Eltoukhy, Guardant Health co-CEO.
  • [1], [2]
    "We are very excited to be partnering with Guardant Health, a global leader in CGP testing, to bring a world-class testing platform to China.
  • "With our CAP accredited laboratory in Shanghai, we are delighted to partner with Guardant Health to make its cancer tests available for biopharmaceutical partners in China."
  • Guardant Health has commercially launched Guardant360, Guardant360 CDx, Guardant360 TissueNext, Guardant360 Response, and GuardantOMNI tests for advanced stage cancer patients, and Guardant Reveal for early-stage cancer patients.

Bayer Receives FDA Fast Track Designation for asundexian Stroke Program

Retrieved on: 
Thursday, February 10, 2022

Bayer today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational drug asundexian (BAY2433334) as a potential treatment for secondary prevention in patients with a non-cardioembolic ischemic stroke.

Key Points: 
  • Bayer today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational drug asundexian (BAY2433334) as a potential treatment for secondary prevention in patients with a non-cardioembolic ischemic stroke.
  • Fast Track Designation is intended to facilitate the development and expedite the review of drug candidates to treat serious medical conditions and fulfill unmet medical needs.
  • The purpose of the program is to get important new therapeutics to the patient earlier.
  • A drug candidate that receives Fast Track Designation may be eligible for more frequent interactions with the FDA to discuss the drug candidates development plan and, if relevant criteria are met, eligibility for Accelerated Approval and Priority Review.5
    We are pleased that asundexian has received Fast Track Designation from the FDA, underscoring the urgent need for additional effective therapies to treat secondary stroke prevention, said Hardi Mundl, M.D., group head thrombosis, clinical development and operations, Bayer.

Orthopedic Spine Surgeon Dr Kingsley R Chin Unprecedented Impact On Pain Management With Record 16 Clinical Abstract Presentations at NANS 2022 Annual Meeting in Orlando

Retrieved on: 
Monday, January 10, 2022

It is a major break from tradition and a precedent to have an orthopedic spine surgeon attend a predominant pain management annual conference such as the NANS 2022 Annual Meeting.

Key Points: 
  • It is a major break from tradition and a precedent to have an orthopedic spine surgeon attend a predominant pain management annual conference such as the NANS 2022 Annual Meeting.
  • Eight abstracts will be presented on Inspan for patients who had spinal stenosis and degenerative disc disease who needed spinal fusion.
  • NanoFuse is the only FDA-cleared combination of DBM and bioactive glass and is indicated for use in orthopedic surgery.
  • The Inspan Spinous Process Plate System is a posterior non-pedicle supplemental fixation system intended for use in the non-cervical spine (T1-S1).

Late-Breaking Phase 2 Data for Investigational Oral Factor XIa Inhibitor Milvexian Suggest Favorable Antithrombotic Profile Across a Wide Range of Doses

Retrieved on: 
Monday, November 15, 2021

Across a 16-fold range of doses, milvexian demonstrated a low risk of major plus CRNM bleeding, with no major bleeds and no dose-response on this composite outcome.

Key Points: 
  • Across a 16-fold range of doses, milvexian demonstrated a low risk of major plus CRNM bleeding, with no major bleeds and no dose-response on this composite outcome.
  • The clear dose efficacy response without increased bleeding provides additional evidence to support our belief in the promise of milvexian.
  • The TKR study is the first of two studies to read out from the Phase 2 milvexian program.
  • Milvexian is a potential first-in-class oral factor XIa (FXIa) inhibitor (anti-thrombotic) for the prevention and treatment of major thrombotic conditions.

Xia Ding Named to USANA Health Sciences’ Board of Directors

Retrieved on: 
Tuesday, October 12, 2021

USANA Health Sciences, Inc. (NYSE: USNA) today announced the appointment of Xia Ding to the companys board of directors effective October 11, 2021.

Key Points: 
  • USANA Health Sciences, Inc. (NYSE: USNA) today announced the appointment of Xia Ding to the companys board of directors effective October 11, 2021.
  • With the addition of Ms. Ding to the board as an independent director, the USANA board now has eight members, six of whom are independent.
  • Kevin Guest, Chief Executive Officer and Chairman of the Board, commented, Im delighted to welcome Ms. Ding to USANA's board.
  • Ms. Ding commented, I am honored to join the USANA board and welcome the opportunity to be part of the companys vision of improving the health and wellness of its customers, employees, and stakeholders around the world.

SEC Obtains Emergency Relief Against New York Real Estate Developer Charged with EB-5 Securities Fraud

Retrieved on: 
Tuesday, September 28, 2021

The funds were allegedly raised for Xia's two real estate development projects the Eastern Mirage project and the Eastern Emerald project.

Key Points: 
  • The funds were allegedly raised for Xia's two real estate development projects the Eastern Mirage project and the Eastern Emerald project.
  • The SEC's complaint, filed in federal district court in Brooklyn, New York, charges Xia and Fleet with violating the anti-fraud provisions of the federal securities laws.
  • The complaint seeks, among other relief, a permanent injunction, disgorgement, prejudgment interest, civil penalties, an asset freeze, and the appointment of a monitor.
  • The complaint also names Xia's wife, Julia Yue (aka JiQing Yue), as a relief defendant and seeks disgorgement and prejudgment interest from her.

Industry leader Huaxia Cultural Tourism group earns two top awards from leading global trade associations, TEA and IAAPA

Retrieved on: 
Wednesday, March 4, 2020

Huaxia Cultural Tourism Group is also being recognized as a pioneer of environmental restoration in connection with one of the awards.

Key Points: 
  • Huaxia Cultural Tourism Group is also being recognized as a pioneer of environmental restoration in connection with one of the awards.
  • Both the awarded shows were produced by Huaxia Cultural Tourism Group as part of its "Legend" spectacle series, realizing the artistic and business vision of Huaxia Chairman Xia Chunting.
  • These globally recognized awards confer worldwide recognition and acclaim to Huaxia Cultural Tourism Group as a leader in the development, production and operation of major entertainment and cultural destinations."
  • The awards confer worldwide recognition and acclaim to Huaxia Cultural Tourism Group as an innovative leader in cultural tourism development, a flourishing international sector driving tourism growth.